Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00818584 · ClinicalTrials.gov registry record · Phase 1

An Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Micafungin in Neonates

A Phase 1 study, sponsored by Astellas Pharma.

Completed
Registry status
Phase 1
Development phase
13
Enrollment target

NCT00818584 is a Phase 1 study that has completed, run by Astellas Pharma. The registered enrollment target is 13 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00818584, a Phase 1 study, has completed, sponsored by Astellas Pharma.

COMPLETED
Registry status
Phase 1
Development phase
13 participants
Enrollment target

Study Summary

This study will evaluate pharmacokinetics and safety of intravenous micafungin in neonates with suspected candida infection

Interventions

  • DRUG Micafungin

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2007-08
Est. Completion 2007-10
Phase Phase 1

Sponsor

Astellas Pharma

165 total trials

What the Registry Record Tells You About NCT00818584

The ClinicalTrials.gov registry entry for NCT00818584 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Micafungin is the first listed.

NCT00818584 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00818584 about?

NCT00818584 is a clinical study titled "An Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Micafungin in Neonates". This study will evaluate pharmacokinetics and safety of intravenous micafungin in neonates with suspected candida infection

What is the current status of trial NCT00818584?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2007-08. Estimated completion is 2007-10.

What interventions are being tested in trial NCT00818584?

The interventions under investigation include: Micafungin (DRUG).

Who is sponsoring clinical trial NCT00818584?

This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.